Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J L Schultze

Showing results (1-10 of 42) with videos related to

Pageof 5
Sort By:
Hematological Oncology|August 1, 1997
Vaccination as immunotherapy for B cell lymphomaJ L Schultze
Leukemia & Lymphoma|February 26, 1999
Why do B cell lymphoma fail to elicit clinically sufficient T cell immune responses?J L Schultze
Advances in Protein Chemistry and Structural Biology|January 7, 2017
Chromatin Remodeling in Monocyte and Macrophage ActivationJ L Schultze
Trends in Immunology|August 30, 2001
From cancer genomics to cancer immunotherapy: toward second-generation tumor antigensJ L Schultze, R H Vonderheide
Cancer Treatment and Research|January 1, 1997
The detection of minimal residual disease: implications for bone marrow transplantationJ G Gribben, J L Schultze
Journal of Molecular Medicine (Berlin, Germany)|March 25, 1999
T cell mediated immunotherapy for B cell lymphomaJ L Schultze, L M Nadler
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1996
Minimal residual disease in non-Hodgkin's lymphomaJ L Schultze, J G Gribben
Klinische Wochenschrift|June 18, 1991
Demonstration of specifically sensitized lymphocytes in patients treated with an aqueous mistletoe extract (Viscum album L.)J L Schultze, A Stettin, P A Berg
Journal of Molecular Medicine (Berlin, Germany)|February 19, 1999
Minimal residual disease detection after myeloablative chemotherapy in chronic lymphatic leukemiaJ L Schultze, J W Donovan, J G Gribben
Cytotherapy|June 19, 2004
DCs in lymphoma--biology and therapeutic aspectsJ L Schultze, F Fiore, M von Bergwelt-Baildon
Pageof 5

Showing results (1-10 of 42) with videos related to

Sort By:
Pageof 5
Hematological Oncology|August 1, 1997
Vaccination as immunotherapy for B cell lymphomaJ L Schultze
Leukemia & Lymphoma|February 26, 1999
Why do B cell lymphoma fail to elicit clinically sufficient T cell immune responses?J L Schultze
Advances in Protein Chemistry and Structural Biology|January 7, 2017
Chromatin Remodeling in Monocyte and Macrophage ActivationJ L Schultze
Trends in Immunology|August 30, 2001
From cancer genomics to cancer immunotherapy: toward second-generation tumor antigensJ L Schultze, R H Vonderheide
Cancer Treatment and Research|January 1, 1997
The detection of minimal residual disease: implications for bone marrow transplantationJ G Gribben, J L Schultze
Journal of Molecular Medicine (Berlin, Germany)|March 25, 1999
T cell mediated immunotherapy for B cell lymphomaJ L Schultze, L M Nadler
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1996
Minimal residual disease in non-Hodgkin's lymphomaJ L Schultze, J G Gribben
Klinische Wochenschrift|June 18, 1991
Demonstration of specifically sensitized lymphocytes in patients treated with an aqueous mistletoe extract (Viscum album L.)J L Schultze, A Stettin, P A Berg
Journal of Molecular Medicine (Berlin, Germany)|February 19, 1999
Minimal residual disease detection after myeloablative chemotherapy in chronic lymphatic leukemiaJ L Schultze, J W Donovan, J G Gribben
Cytotherapy|June 19, 2004
DCs in lymphoma--biology and therapeutic aspectsJ L Schultze, F Fiore, M von Bergwelt-Baildon
Pageof 5